MedPath

Which one is more effective in cyclic vomiting syndrome treatment? Topitamate or Amitriptyline ?

Phase 2
Conditions
Cyclical vomiting syndrome.
Nausea and vomiting
Registration Number
IRCT2015102316844N2
Lead Sponsor
Vice Chancellor for Research of Isfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Children 3-15
years old with diagnosis of cyclic vomiting syndrome (based on Rome III criteria: 1 Stereotypical episodes of vomiting regarding onset (acute) and duration (less than 1 week); 2) Three or more discrete episodes in the prior year; and 3) Absence of nausea and vomiting between episodes and absence of metabolic, gastrointestinal, central nervous system structural or biochemical disorders); Normal Neurological and Developmental examination Exclusion criteria: Known metabolic disease; Obstructive disease of gastrointestinal or urinary system; Patients who don't give consent to participate in the study or want to leave the study anytime.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of cyclic vomiting syndrome. Timepoint: for 3 months after starting the medication. Patients are followed every two weeks after starting the medication. Method of measurement: questionnaire (evaluating number of attacks and duration of attacks).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath